Seifarth C, Schehler B, Schneider H J
Practice for Endocrinology, Regensburg, Germany.
Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):27-31. doi: 10.1055/s-0032-1327734. Epub 2012 Nov 12.
The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results. Moreover, the effectiveness in a real-life outpatient setting has not been tested until today. In this study we aimed to examine the effectiveness of metformin as a weight reducing drug in obese and overweight patients with regard to their degree of insulin resistance.
We treated 154 consecutive patients with a body mass index ≥27 kg/m(2) in an outpatient setting over 6 months with metformin up to a dosage of 2,500 mg per day. Additionally, we included 45 untreated patients as controls. Patients were monitored for weight changes over 6 months. Before metformin treatment was started insulin sensitivity was determined in all patients by calculating HOMA index and Matsuda index after a 75 g oral glucose tolerance test.
The mean weight loss in the metformin treated group was 5.8±7.0 kg (5.6±6.5%). Untreated controls gained 0.8±3.5 kg (0.8±3.7%) on average. Patients with severe insulin resistance lost significantly more weight as compared to insulin sensitive patients. The percentage of weight loss was independent of age, sex or BMI.
Metformin is an effective drug to reduce weight in a naturalistic outpatient setting in insulin sensitive and insulin resistant overweight and obese patients.
二甲双胍治疗肥胖症的疗效在少数临床试验中得到评估,但结果尚无定论。此外,其在现实门诊环境中的有效性至今尚未得到检验。在本研究中,我们旨在探讨二甲双胍作为减肥药物对肥胖和超重患者胰岛素抵抗程度的有效性。
我们在门诊环境中对154例连续的体重指数≥27kg/m²的患者进行了为期6个月的治疗,给予二甲双胍,剂量最高达每日2500mg。此外,我们纳入了45例未治疗的患者作为对照。对患者进行6个月的体重变化监测。在开始二甲双胍治疗前,所有患者在进行75g口服葡萄糖耐量试验后,通过计算HOMA指数和松田指数来确定胰岛素敏感性。
二甲双胍治疗组的平均体重减轻为5.8±7.0kg(5.6±6.5%)。未治疗的对照组平均体重增加了0.8±3.5kg(0.8±3.7%)。与胰岛素敏感患者相比,严重胰岛素抵抗患者体重减轻明显更多。体重减轻的百分比与年龄、性别或体重指数无关。
在自然主义的门诊环境中,二甲双胍是一种能有效减轻胰岛素敏感和胰岛素抵抗的超重及肥胖患者体重的药物。